Immunotherapy represents a paradigm shift in oncology treatment. The goal of
immunotherapy is to overcome immunosuppression induced by a tumour and its …

In the past decade, we have witnessed the revolution in cancer therapy, especially in the
rapid development of cancer immunotherapy. In particular, the introduction of nanomedicine …

Background It is unclear whether the chemotherapy response improves after exposure to
immunotherapy. Antiangiogenic agents have been shown to stimulate the immune system …

Background The efficacy and safety of chemotherapy (CTx) after anti-PD-1 therapy in
patients with advanced gastric cancer (AGC) remains unclear. Methods Medical records of …

Background There are still few data on the activity and safety of cetuximab-based salvage
chemotherapy after immunotherapy (SCAI) in patients with squamous cell cancer of the …

Abstract Background Trifluridine/tipiracil (FTD/TPI) prolongs survival in the third-or later-line
treatment for advanced gastric cancer (GC), esophagogastric junction (EGJ) …

Through our involvement in KEYNOTE‐059, we unexpectedly observed durable responses
in two patients with metastatic gastroesophageal adenocarcinoma (mGEA) who received …

Esophageal cancer is the eighth most common malignancy and the sixth leading cause of
cancer-related deaths worldwide. Chemotherapy based on platinum drugs, 5-fluorouracil …

Introduction Routine blood tests are prognostic tests for patients with cholangiocarcinoma.
New drug regimens may produce a median overall survival of 2 years or more. Methods This …

Background Patients have difficult unmet needs when standard chemotherapy produces a
median survival of less than 1 year or many patients will experience severe toxicities. Blood …